马斯平与凯福隆随机对照治疗老年细菌性下呼吸道感染临床分析  

CLINICAL ANALYSIS OF THE THERAPEUTIC EFFECT OF MAXIPIME AND CLAFORAN IN AGED PATIENTS WITH BACTERIAL LOWER-RESPIRATORY INFECTION

作　　者：包云[1] 蒋有娟[1] 申彤蕾[1] 李鸣[1] 

机构地区：[1]扬州市第一人民医院,扬州225001

出　　处：《江苏临床医学杂志》2001年第1期28-30,共3页Journal of Jiangsu Clinical Medicine

摘　　要：目的 :评价马斯平治疗老年细菌性下呼吸道感染的临床疗效和安全性。方法 :将 68例老年细菌性下呼吸道感染患者随机分为试验组和对照组 ,分别给马斯平或凯福隆治疗。结果 :两组痊愈率分别为 5 8 8%和 2 6 5 % ,总有效率分别为91 2 %和 67 6% ;治疗后细菌清除率分别为 89 7%和 63 3 % ,两组比较无显著性差异。结论 :马斯平抗菌谱广 ,疗效好 ,不良反应轻微 ,对老年细菌性下呼吸道感染是一种安全、有效的治疗药物。Objective:To evaluate the curative effect and safey of Maxipime(Cefepime) in aged patients with bacterial lower-respiratory infection.Methods:Sixty-eight patients were divided into text group and contral group at radom. The cases in the test group were treated with maxipime, while the ones in the control group with Claforan(Cefotaxime).Results:The cure rates of the two groups were 58.8% and 26.5% respectively, the overal offective rates were 91.2%(30/34) and 67.6%(23/34), and bacterial clearance rates were 89.7% and 63.3%. No significant difference was noticed between the Maxipime group and the Claforan one.Conclusion:Maxipime has a good theraputic efficacy and safety in the treatment of aged patients with bacterial lower-respiratory infections.

关 键 词：马斯平 凯福隆 老年人下呼吸道感染 临床疗效 安全性 

分 类 号：R560.5[医药卫生—呼吸系统] R969.4[医药卫生—内科学]